A Study of PY314 in Subjects With Advanced Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Gynecologic Cancer|Breast Cancer|Colorectal Cancer|Lung Adenocarcinoma|Renal Cell Carcinoma|Triple Negative Breast Cancer|Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer|Ovarian Cancer
Interventions: DRUG: PY314|DRUG: Combination Therapy: PY314 + Pembrolizumab
Sponsor: Pionyr Immunotherapeutics Inc.